{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:28:39Z","timestamp":1777418919035,"version":"3.51.4"},"reference-count":71,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the microbiology, pharmacokinetic parameters, drug interactions, and results of the available clinical trials of gemifloxacin for the treatment of community-acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>MEDLINE (1966\u2013September 2003) was searched for primary and review articles. Data from the manufacturer were also included. Key words included adverse effects, clinical trials, drug interactions, gemifloxacin, and pharmacokinetic parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                    <jats:p>All articles and product labeling concerning gemifloxacin, a fluoroquinolone antibiotic recently approved by the Food and Drug Administration for treatment of CAP and AECB, were included for review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Compared with currently available fluoroquinolones, gemifloxacin demonstrated improved in vitro activity against Streptococcus pneumoniae (minimum inhibitory concentration for 90% eradication 0.03 \u03bcg\/mL) and similar activity against gram-negative respiratory pathogens ( Haemophilus influenzae, Moraxella catarrhalis) and atypical pathogens such as Chlamydia pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae. Gemifloxacin, consistent with other available fluoroquinolones, has insufficient activity against methicillin-resistant Staphylococcus aureus to allow clinical use for such infections. Gemifloxacin has adequate bioavailability and a favorable drug interaction profile. Gemifloxacin was comparable to commonly employed nonfluoroquinolone regimens for treatment of CAP and AECB, although the studies were designed to demonstrate equivalence. Gemifloxacin once daily for 5\u20137 days was well tolerated in controlled and uncontrolled clinical studies. Available clinical data, however, are insufficient to draw clinical or toxicologic distinctions between gemifloxacin and other fluoroquinolones.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Gemifloxacin may be a suitable choice for empiric treatment of CAP or AECB. However, due to the significant history of fluoroquinolone-induced hepatic failure and dermatologic complications, the use of this drug should be closely monitored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1e003","type":"journal-article","created":{"date-parts":[[2004,6,15]],"date-time":"2004-06-15T14:08:57Z","timestamp":1087308537000},"page":"1226-1235","source":"Crossref","is-referenced-by-count":41,"title":["Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections"],"prefix":"10.1177","volume":"38","author":[{"given":"Bong K","family":"Yoo","sequence":"first","affiliation":[{"name":"Bong K Yoo PharmD PhD, Assistant Professor, College of Pharmacy, Yeungnam University, Dae-dong Kyungsansi, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren M","family":"Triller","sequence":"additional","affiliation":[{"name":"Darren M Triller PharmD, Assistant Professor, Albany College of Pharmacy, Albany, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Soon","family":"Yong","sequence":"additional","affiliation":[{"name":"Chul-Soon Yong PhD, Professor, College of Pharmacy, Yeungnam University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P","family":"Lodise","sequence":"additional","affiliation":[{"name":"Thomas P Lodise PharmD, Assistant Professor, Albany College of Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,7,1]]},"reference":[{"key":"bibr1-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/.61.3.377-392.1997"},{"key":"bibr2-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1086\/514923"},{"key":"bibr3-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.274-282.2003"},{"key":"bibr4-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1135(03)00129-9"},{"key":"bibr5-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.65.070196.003223"},{"key":"bibr6-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1086\/321846"},{"key":"bibr7-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1007\/BF02491502"},{"key":"bibr8-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3112-3117.2000"},{"key":"bibr9-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.413-419.2002"},{"key":"bibr10-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1089\/107662902760190617"},{"key":"bibr11-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf022"},{"key":"bibr12-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2032"},{"key":"bibr13-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2956"},{"key":"bibr14-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1177"},{"key":"bibr15-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.304-310.2000"},{"key":"bibr16-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1973"},{"key":"bibr17-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1835"},{"key":"bibr18-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-7646(98)80023-X"},{"key":"bibr19-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.4.685"},{"key":"bibr20-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.5.583"},{"key":"bibr21-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.798-801.2000"},{"key":"bibr22-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.329"},{"key":"bibr23-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.410"},{"key":"bibr24-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.2000"},{"key":"bibr25-aph.1E003","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2003","edition":"6"},{"key":"bibr26-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00341-8"},{"key":"bibr27-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00431-9"},{"key":"bibr28-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00198-X"},{"key":"bibr29-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00092-X"},{"key":"bibr30-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1721-1729.2001"},{"key":"bibr31-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3008-3011.2000"},{"key":"bibr32-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_3.23"},{"key":"bibr33-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_3.1"},{"key":"bibr34-aph.1E003","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2002.17.6.737"},{"key":"bibr35-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00124-3"},{"key":"bibr36-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00104-7"},{"key":"bibr37-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00173-4"},{"key":"bibr38-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2962-2968.2000"},{"key":"bibr39-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1159\/000048508"},{"key":"bibr40-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jac.a020888"},{"key":"bibr41-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050446"},{"key":"bibr42-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00083-9"},{"key":"bibr43-aph.1E003","unstructured":"Factive (gemifloxacin) briefing document, NDA #21-158: P026, January 28, 2003. www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3931B1_01_LG%20Life%20Sciences-Factive.pdf (accessed 2004 May 25)."},{"key":"bibr44-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_3.41"},{"key":"bibr45-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2176-2178.2000"},{"key":"bibr46-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.suppl_3.29"},{"key":"bibr47-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2806"},{"key":"bibr48-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3351-3356.2000"},{"key":"bibr49-aph.1E003","unstructured":"Sens K, Mietzner S, Sagnimeni A, Stout JE, Yu VL. Activity of new quinolones, macrolide, and ketolide against 100 strains of\n                      Legionella\n                      species using broth dilution and intracellular susceptibility testing methods. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17\u201320, 2000."},{"key":"bibr50-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.312-315.2001"},{"key":"bibr51-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1604-1608.2000"},{"key":"bibr52-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(01)00080-7"},{"key":"bibr53-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.540-545.2001"},{"key":"bibr54-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1007\/BF02976379"},{"key":"bibr55-aph.1E003","volume-title":"Factive (gemifloxacin)","year":"2003"},{"key":"bibr56-aph.1E003","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200059050-00009"},{"issue":"4","key":"bibr57-aph.1E003","first-page":"435","volume":"29","author":"Ramji JV","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"bibr58-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1159\/000007245"},{"key":"bibr59-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00187-4"},{"key":"bibr60-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1159\/000007244"},{"key":"bibr61-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1159\/000007241"},{"key":"bibr62-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1159\/000007242"},{"key":"bibr63-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00181-3"},{"key":"bibr64-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80088-1"},{"key":"bibr65-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.1.67"},{"key":"bibr66-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85139-6"},{"key":"bibr67-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2003.1435"},{"key":"bibr68-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00359-4"},{"key":"bibr69-aph.1E003","doi-asserted-by":"publisher","DOI":"10.1159\/000007246"},{"key":"bibr70-aph.1E003","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262010-00002"},{"key":"bibr71-aph.1E003","unstructured":"Bird N, Lewis A, Montague T. Assessment of the effect of gemifloxacin on QTc interval in healthy volunteers (poster 821). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17\u201320, 2000."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1E003","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:40Z","timestamp":1777374520000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1E003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":71,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1345\/aph.1E003"],"URL":"https:\/\/doi.org\/10.1345\/aph.1e003","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}